Graves Disease Clinical Trials 2024

Graves Disease Clinical Trials 2024

Graves Disease research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in graves disease clinical trials today.

Popular filter options for graves disease trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to graves disease

What are the top hospitals conducting graves disease research?

In the realm of clinical trials for Graves' disease, one hospital stands out as a pioneer in research and treatment. Located in Baltimore, Maryland, Johns Hopkins Hospital has taken up the mantle to tackle this complex autoimmune disorder. While they currently have just one active trial dedicated to Graves' disease, it is a significant step forward in understanding and finding potential solutions for this condition. The hospital's commitment to advancing medical knowledge is evident as they recorded their first-ever trial for Graves' disease in 2018.

Graves' disease is an autoimmune disorder that affects the thyroid gland, leading to its overactivity and resulting in symptoms such as weight loss, rapid heartbeat, anxiety, and bulging eyes (a condition called exophthalmos). It primarily affects women between the ages of 20 and 40 but can also occur in men and children.

Johns Hopkins Hospital's involvement in researching Graves' disease highlights the importance of continuous exploration into rare or lesser-known conditions. By conducting clinical trials focused specifically on this ailment, researchers aim to improve our understanding of its underlying mechanisms and develop effective treatments. Through their efforts at Johns Hopkins Hospital - renowned for its expertise across various medical disciplines - patients with Graves' disease can find hope not only through cutting-edge care but also through groundbreaking research paving the way towards better management strategies.

Which are the best cities for graves disease clinical trials?

When it comes to graves disease clinical trials, Baltimore, Maryland emerges as a leading city in research and development. With 1 active trial underway, the city focuses on important investigations such as the Pilot Project and other promising interventions. This commitment to advancing knowledge and treatment options for graves disease brings hope to patients seeking innovative approaches in managing their condition.

Which are the top treatments for graves disease being explored in clinical trials?

Graves disease, a thyroid disorder affecting thousands of individuals worldwide, is the focus of ongoing clinical trials exploring innovative treatment options. Among the top treatments being investigated are:

  • Teprotumumab: This drug shows promise in alleviating Graves' ophthalmopathy symptoms and has demonstrated positive results in multiple trials.
  • Rituximab: An immunosuppressive medication commonly used to treat other autoimmune conditions, it is being tested for its efficacy in managing Graves disease as well.
  • Tocilizumab: Originally developed for rheumatoid arthritis, this biologic agent is now being evaluated for its potential benefits in treating Graves' orbitopathy.

Through these clinical trials, researchers aim to advance medical knowledge and offer new avenues of hope for those affected by Graves disease.

What are the most recent clinical trials for graves disease?

In recent clinical trials, promising advancements have been made in the treatment of Graves' disease. Researchers are investigating new therapies and approaches to better manage this autoimmune disorder. One study focuses on the use of novel immunomodulatory drugs to target specific pathways involved in the development of Graves' disease. Another trial explores the potential benefits of complementary treatments like acupuncture or herbal medicine as adjunctive therapies for symptom relief. These ongoing studies offer hope for improved outcomes and quality of life for individuals living with Graves' disease.

What graves disease clinical trials were recently completed?

Recently, several clinical trials focusing on the treatment of Graves' disease have successfully concluded. These studies signify significant progress in combating this autoimmune disorder. Notably, a trial sponsored by Roche Pharmaceuticals investigated the efficacy and safety of their experimental drug RVT-1401 and was completed in November 2021. Another trial conducted by Eli Lilly and Company assessed the effectiveness of their medication LY3337641 and wrapped up in September 2020. These recent developments highlight the ongoing efforts to improve therapies for individuals with Graves' disease, offering hope for better management of this condition in the future.